

DDN SYMPOSIUM

ADVANCES IN IMMUNO-ONCOLOGY

	DAY 1 AUGUST 26th	
TIME (ET)	SESSION	
11:00 AM	The next generation of precision oncology: Integrating personalized medicine to improve cancer outcomes Nathan Goodyear, PhD, Williams Cancer Institute	
12:30 PM	TCR sequencing in the Eyquem Lab Charlotte Wang, PhD, University of California, San Francisco	
1:00 PM	Identifying and characterizing tumor-reactive TIL in the tumor microenvironment Zhen Zeng, PhD, Johns Hopkins Medicine	
1:45 PM	Engineering mechanistic clarity: how antibody design decisions shape targeted antibody therapies Rebecca Argyros, Bio X Cell	
2:00 PM	Harnessing innate immunity and the ELANE pathway to selectively kill cancer cells and activate anti-tumor immunity Chang Cui, PhD, Onchilles Pharma	
2:45 PM	From target engagement to functionality: research tools for multi-specific immune cell engager antibodies Veronique Baron, BPS Bioscience, Inc.	
3:00 PM	Overcoming the bloodstream barrier: systemic delivery of enveloped virotherapies to target metastatic disease Eric Poma, Calidi Biotherapeutics	
	DAY 2 AUGUST 27th	
TIME (ET)	SESSION	
11:00 AM	CD28 T cell engagers in prostate cancer Bilal A. Siddiqui, M.D., MD Anderson Cancer Center	
11:22 AM	Building the tumor microenvironment in 3D: multicellular models for developing anti-cancer and immunotherapy approaches Matthieu Spriet, PhD, Inventia Life Science	
11:50 AM	Novel IO therapeutic strategies for targeting cancer and metastasis Anwar Murtaza, PhD, Syngene International Ltd	
12:30 PM	From biospecimens to patient-derived models for immuno-oncology research Bradley N. Mills, PhD, University of Rochester Medical Center	
1:20 PM	Curing myeloma with immune therapy Sagar Lonial, MD, Winship Cancer Institute of Emory University	
2:00 PM	Translating tumor microenvironment biology into a clinically accessible blood-based assay Mirna Jarosz, PhD, LiquidCell Dx	